stock moves
uniQure shares soar on Huntington's data
uniQure was the best-performing biopharma stock yesterday, with shares jumping 76% after the company reported positive data on its experimental gene therapy for Huntington's disease.
Updated interim data from a Phase 1/2 trial showed that at two years, nine patients who received the high dose of the drug had a 0.2 point decrease on a measure of disease progression called cUHDRS. That compares with a 1 point decrease in an external control group based on natural history studies. These data suggest there was an 80% slowing of disease progression in the treated patients.
Analysts said the future of this drug, though, will depend largely on how uniQure's discussions with regulators go, particularly whether it will be okay to use a natural history control group. The company is slated to meet with the FDA in the second half of this year to discuss the possibility of accelerated approval.
biotech
Why Amylyx is betting on a GLP-1 antagonist
After pulling its ALS drug from the market following a failed trial, Amylyx has now acquired a GLP-1 receptor antagonist from Eiger BioPharmaceuticals. The company plans to start a Phase 3 program next year to test the drug in a condition called post-bariatric hypoglycemia, it said in a press release today. I chatted briefly with co-CEOs Justin Klee and Joshua Cohen about this decision.
First, to be clear, this drug is not in the same class as the highly popular diabetes and obesity drugs — those are GLP-1 receptor agonists. The drug that Amylyx has acquired, called avexitide, blocks GLP-1 receptors and has been tested in rare settings: post-bariatric hypoglycemia and congenital hyperinsulinism. In both conditions, patients's insulin levels are too high and they experience dangerously low blood sugar. The CEOs said those patients also have elevated levels of the GLP-1 hormone (which promotes insulin secretion), and avexitide is designed to help patients return to normal physiologic GLP-1 levels.
I asked Klee and Cohen why they opted for this drug, given Amylyx's historic focus on neurodegenerative diseases. The CEOs noted that they've long studied a candidate in Wolfram syndrome, a rare genetic disorder that causes childhood-onset diabetes, and the new drug expands on their work in endocrinology. So now, they see the two primary areas of focus for the company as neuro and endocrine conditions, they said.
In developing endocrine drugs, there are established outcomes to measure in trials, such as glucose and insulin levels, whereas for neurodegenerative conditions, there's still ongoing research on better biomarkers to measure disease, Cohen said.
people moves
Pfizer's chief scientific officer to step down
After serving as Pfizer's chief scientific officer for 15 years, through the tenures of three CEOs, Mikael Dolsten will be stepping down once he helps find his replacement.
My colleague Matt Herper looked back at the ups and downs of Dolsten's tenure. A key highlight was Pfizer's performance during the Covid-19 pandemic, when the company and its partner BioNTech beat Moderna to be the first to bring a Covid vaccine to market.
But more recently, Pfizer has failed to deliver on investors' expectations, with the company's shares now trading at about half where they were during their pandemic peak.
Read more.
drug pricing
FTC goes after PBMs in new report
The FTC released a lengthy report yesterday that said pharmacy benefit managers wield "enormous power" that can affect which drugs are available, at what price, and which pharmacies patients can use to get medications.
The three largest PBMs — Caremark Rx, Express Scripts, and OptumRx —processed nearly 80% of the roughly 6.6 billion prescriptions dispensed by U.S. pharmacies in 2023, the FTC said.
Additionally, PBMs, which are now part of massive conglomerates that also consist of big insurers and pharmacy chains, impose unfair and harmful contractual terms on independent pharmacies that can put them out of business, according to the report.
Read more from STAT's Ed Silverman.
No comments